BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

A federal jury in San Francisco returned a guilty verdict for Rowland Marcus Andrade, the founder and CEO of NAC Foundation ...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it will participate at the 37th Annual Roth ...

A healthy financial institution is well equipped to counteract anti-money laundering and combat the financing of terrorism, ...

Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.

Kura Oncology's (KURA) ziftomenib shows AML promise amid competition. See why I'm inclined to view the current price levels ...

Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – – sNDA filing for revumenib ...

Revuforj® (revumenib) net product revenue in initial five weeks of launch - - Launched Niktimvo (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte - - sNDA ...

A panel of 10 expert hematologists created recommendations for optimal MRD-guided ALL treatment, which were recently ...

Dasari, MD, MS, discussed data from multiple ASCO Gastrointestinal Cancers Symposium presentations highlighting the use of circulating tumor DNA as a minimal residual disease in colorectal cancer.

Good day, everyone, and welcome to today's Q4 2024 Kura Oncology, Inc., financial results conference call. (Operator Instructions) Please note this call is being recorded. It is now my pleasure to ...

Initial clinical data from global Phase 1 study of CLN-978 in Systemic Lupus Erythematosus (SLE) expected in Q4 2025; CLN-978 remains the first ...